NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development25,02432,63814,577
Selling General and Administrative13,09912,6238,885
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-38,123-45,261-23,462
Income from Continuing Operations
Total Other Income/Expenses Net164174166
Earnings Before Interest and Taxes-37,959-45,087-23,296
Interest Expense---
Income Before Tax-37,959-45,087-23,296
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-37,959-45,087-23,296
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-37,959-45,087-23,296
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-37,959-45,087-23,296